Ozarelix

Phase 2Small molecule

Spectrum Pharmaceuticals, Inc

Ozarelix is one of 70 small molecule programs targeting Benign Prostatic Hyperplasia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Benign Prostatic HyperplasiaActive, not recruiting

Lower Urinary Tract SymptomActive, not recruiting

Prostate CancerActive, not recruiting

Benign Prostatic HyperplasiaPhase 2

Active, not recruiting

Lower Urinary Tract SymptomPhase 2

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Ozarelix

Spectrum Pharmaceuticals, Inc

Phase 2

1 2

Trexall

Alnylam Pharmaceuticals

Preclinical

—3

Viagra

VViatris Specialty LLC

Preclinical

1 4

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 5

Duragesic

CCephalon

Preclinical

1 6

Prednisone/prednisolone

Roche

Preclinical

3 7

Osmitrol

BB. Braun Medical Inc.

Preclinical

—8

Ifex

BBaxter Healthcare Corporation

Preclinical

—9

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

—10

Therapeutic Hydrocortisone

EEastern Cooperative Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lower Urinary Tract Symptom1 trial

The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate

Completed· Spectrum Pharmaceuticals, Inc logo

Spectrum Pharmaceuticals, Inc·Phase 2·NCT00427219·74 enrolled

Benign Prostatic Hyperplasia1 trial

Trial of the Safety and Efficacy of Ozarelix in Participants With Benign Prostatic Hyperplasia (BPH)

Terminated· Spectrum Pharmaceuticals, Inc logo

Spectrum Pharmaceuticals, Inc·Phase 2·NCT00743184·28 enrolled

Prostate Cancer1 trial

International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer

Completed· Spectrum Pharmaceuticals, Inc logo

Spectrum Pharmaceuticals, Inc·Phase 2·NCT01252693·203 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Ozarelix. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ozarelix compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ozarelix. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Spectrum Pharmaceuticals, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Spectrum Pharmaceuticals, Inc

Ozarelix

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lower Urinary Tract Symptom1 trial

Benign Prostatic Hyperplasia1 trial

Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News